PRMT1 inhibitor
/ Cancer Therapeutics CRC, Bionomics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 01, 2021
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
(PubMed, Nat Commun)
- "Taken together, our data support PRMT1 as a compelling target in PDAC and informs a mechanism-based translational strategy for future therapeutic development.Statement of significancePDAC is a highly lethal cancer with limited therapeutic options. This study identified and characterized PRMT1-dependent regulation of RNA metabolism and coordination of key cellular processes required for PDAC tumor growth, defining a mechanism-based translational hypothesis for PRMT1 inhibitors."
Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • PRMT1
1 to 1
Of
1
Go to page
1